Risk of urolithiasis due to topiramate as weight loss drug

  • Elias Sharma Associate Professor, Department of Urology, Medical College, Jammu
  • Jaideep M Ratkal Associate Professor Karnataka Institute of Medical Sciences, Hubli
Keywords: Topiramate, Nephrolithiasis, Urolithisis

Abstract

Topiramate is sulfamate-substituted monosaccharide anti-epileptic and migraine drug, recently FDA approved as an anti-obesity medicine. Many reports of symptomatic urolithiasis with Topiramate usage as anti-epileptic and migraine drug are available including those studies with biochemical and stone risk profile. We present cases of symptomatic urolithiasis in patients on Topiramate for weight loss and to express caution that the drug usage should be limited and accompanied by assessment of risk profiles at regular intervals.

Downloads

Download data is not yet available.

Author Biography

Jaideep M Ratkal, Associate Professor Karnataka Institute of Medical Sciences, Hubli

Associate Professor,

Department of Urology

References

York, D. A., Singer, L., Thomas, S., Bray, G. A. Effect of topiramate on body weight and body composition of Osborne‐Mendel rats fed a high‐fat diet: alterations in hormones, neuropeptide, and uncoupling‐protein mRNAs. Nutrition 2000; 16: 967–975.

Reife, R., Pledger, G., Wu, S. C. Topiramate as add‐on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41(Suppl 1): S66–S71.

Moradi S, Kerman SR, Mollabashi M. The effect of topiramate on weight loss in patients with type 2 diabetes. J Res Med Sci. 2013; 18(4): 297-302.

Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005; 96: 243–51.

Kou RL, Moran ME, Kim DH, Abraham HM, White MD, Lingeman JE. Topiramate induced nephrolithiasis. J Endourol. 2002; 16:229-31.

Wasserstein AG, Rak I, Reife RA. Investigation of Mechanistic basis for topiramate associated Nephrolithiasis: Examination of urinary and serum constituents. Epilepsia 1995; 39 Suppl 3): S153.

Welch BJ, Graybeal D, Moe O W, Maalouf N M, Sakhee Khashayar. Biochemical and Stone rick profiles with Topiramate treatment. Am J Kidney Dis 2006; 48(4): 555-563.

Warren BW, La Grange CA, Tucker T, Bensalem-Owen M, Pais VM Jr. Induction of Progressive profound hypocitraturia with increasing dose of topiramate. Urology 2008; 72: 29-32.

Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 3(suppl 3): S153.

Eggener S, Kim SC, User HM, Pazona J, Nadler RB. Urolithiasis associated with Topiramate. Int Braz J Urol. 2004: 30:29-31.
Published
2019-01-09
How to Cite
1.
Sharma E, Ratkal J. Risk of urolithiasis due to topiramate as weight loss drug. IJBR [Internet]. 9Jan.2019 [cited 18Feb.2019];10(1):e5031. Available from: https://ssjournals.com/index.php/ijbr/article/view/5031
Section
Original Research Articles